再鼎医药胃癌新药临床研究因疗效不足终止,相关研发进程受影响

财中社
Nov 05, 2025

  11月5日,再鼎医药(09688/ZLAB)发布公告,公司的合作伙伴安进公司于2025年11月4日宣布,关于贝玛妥珠单抗联合化疗及纳武利尤单抗用于一线胃癌的1b/3期临床研究FORTITUDE-102,由于临时分析显示疗效不足,该研究已被停止。此决定是基于资料监查委员会的要求。

  公司表示将继续与安进公司密切合作,并在适当时提供进一步的更新。此次研究的停止将影响公司的相关研发进程。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10